Correlation of Fecal, Plasma, Serum, and Salivary Calprotectin to Endoscopic and Histologic Outcomes in Patients With Crohn's Disease: A Pilot Study.
Kendra J Kamp, Katrina Hendrickson, Arwa Iqbal and 5 others
PMID 40728846WHAT IT FOUND
In 17 Crohn's disease patients, fecal calprotectin tracked endoscopy, biopsy and symptom activity most closely; plasma was linked to biopsy; saliva did not reflect disease activity.
Key findings
01Fecal calprotectin was the only sample type significantly correlated with clinical, endoscopic, and histologic disease outcomes, and it had the strongest correlation with endoscopy (r=0.83, p<0.01).
02Plasma calprotectin was significantly correlated with histology (r=0.55, p=0.02).
03Salivary calprotectin showed negative correlations with fecal and plasma levels, but these were driven by two individuals with extremely high salivary calprotectin (>30,000 ng/ml).
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
This was a pilot study with 17 patients, and only 6 had active endoscopic disease. The salivary calprotectin correlations were driven by two extreme values, so they may not apply to most patients. Blood and saliva were collected on the colonoscopy day, after bowel preparation, which may have changed their calprotectin levels. Histology was scored by a single pathologist.
Declared interests
Kindra Clark-Snustad serves on advisory boards for Takeda, BMS, Pfizer, and AbbVie. Scott Lee received research support from AbbVie, Janssen, Takeda, Celgene, and Pfizer and serves on advisory boards for Cornerstones Health, Janssen, Eli Lilly, Bristol-Myers Squibb, and Pfizer.
The easy way to misread this
Do not conclude that salivary or plasma calprotectin can replace fecal testing or endoscopy. This was a 17-patient pilot, and the salivary correlations were driven by two extreme samples.